MyLungCancerTeam

The KRAS mutation is relatively common, occurring in up to 30% of people with non-small cell lung cancer (NSCLC). NSCLC accounts for about 80% of all lung cancer cases, making this a well-studied mutation. While specific survival rates for KRAS12v mutations aren't provided in the search results, early-stage lung cancer Show Full Answer

The KRAS mutation is relatively common, occurring in up to 30% of people with non-small cell lung cancer (NSCLC). NSCLC accounts for about 80% of all lung cancer cases, making this a well-studied mutation. While specific survival rates for KRAS12v mutations aren't provided in the search results, early-stage lung cancer generally has better outcomes than advanced stages. The key to better outcomes is early detection and appropriate treatment. There are now specialized resources and treatment options available specifically for people with KRAS mutations, including clinical trials and targeted therapies. It's important to work closely with your oncologist to develop a personalized treatment plan, as they can best evaluate your specific situation and recommend the most appropriate treatment options for your case.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

LUNGevity Launches First of Six Resource Portals for Specific Types of Lung Cancer

Lung Cancer After Another Cancer: Lymphoma, Breast Cancer, and More